

1. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. *Science* 2008;321:1801–1806.
2. Shibata DK, Kern SE. Ancestral trees for modeling stem cell lineages genetically rather than functionally: Understanding mutation accumulation and distinguishing the restrictive cancer stem cell propagation theory and the unrestricted cell propagation theory of human tumorigenesis. *Breast Dis* 2008;29:15–25.
3. Blackford A, Parmigiani G, Kensler TW, et al. Genetic mutations associated with cigarette smoking in pancreatic cancer. *Cancer Res* 2009;69:3681–3688.
4. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. *Nature* 2010;467:1114–1117.
5. Sato N, Mizumoto K, Nakamura M, et al. Centrosome abnormalities in pancreatic ductal carcinoma. *Clin Cancer Res* 1999;5:963–970.
6. Goggins M, Schutte M, Lu J, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. *Cancer Res* 1996;56:5360–5364.
7. Ozcelik H, Schmocker B, Di Nicola N, et al. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. *Nat Genet* 1997;16:17–18.
8. Murphy KM, Brune KA, Griffin C, et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. *Cancer Res* 2002;62:3789–3793.
9. Hahn SA, Greenhalf B, Ellis I, et al. BRCA2 germline mutations in familial pancreatic carcinoma. *J Natl Cancer Inst* 2003;95:214–221.
10. Goggins M, Offerhaus GJA, Higers W, et al. Adenocarcinomas of the pancreas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology: poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. *Am J Pathol* 1998;152:1501–1507.
11. Wilentz RE, Goggins M, Redston M, et al. Genetic, immunohistochemical, and clinical features of medullary carcinomas of the pancreas: a newly described and characterized entity. *Am J Pathol* 2000;156:1641–1651.
12. Hruban RH, Wilentz R, Kern SE. Genetic progression in the pancreatic ducts. *Am J Pathol* 2000;156:1821–1825.
13. van Heek NT, Meeker AK, Kern SE, et al. Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. *Am J Pathol* 2002;161:1541–1547.
14. Gisselsson D, Jonson T, Petersen A, et al. Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors. *Proc Natl Acad Sci U S A* 2001;98:12683–12688.
15. Hiyama E, Kodama T, Shimbara K, et al. Telomerase activity is detected in pancreatic cancer but not in benign tumors. *Cancer Res* 1997;57:326–331.
16. Iwao T, Hiyama E, Yokoyama T, et al. Telomerase activity for the preoperative diagnosis of pancreatic cancer. *J Natl Cancer Inst* 1997;89:1621–1623.
17. Montgomery E, Wilentz RE, Argani P, et al. Analysis of anaphase figures in routine histologic sections distinguishes chromosomally unstable from chromosomally stable malignancies. *Cancer Biol Ther* 2003;2:248–252.
18. Cox AD, Der CJ. Ras family signaling: therapeutic targeting. *Cancer Biol Ther* 2002;1:599–606.
19. Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. *Cell* 1988;53:549–554.
20. Caldas C, Hahn SA, Hruban RH, et al. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. *Cancer Res* 1994;54:3568–3573.
21. Klimstra DS, Longnecker DS. K-ras mutations in pancreatic ductal proliferative lesions. *Am J Pathol* 1994;145:1547–1550.
22. Kanda M, Matthaei H, Wu J, et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. *Gastroenterology* 2012;142:730–773.e9.
23. Lerner EC, Qian Y, Blaskovich MA, et al. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. *J Biol Chem* 1995;270:26802–26806.
24. Cox AD, Der CJ. Farnesyltransferase inhibitors: promises and realities. *Curr Opin Pharmacol* 2002;2:388–393.
25. Riggins GJ, Thiagalingam S, Rozenblum E, et al. Mad-related genes in the human. *Nat Genet* 1996;13:347–349.
26. Zavel L, Dai JL, Buckhaults P, et al. Human Smad3 and Smad4 are sequence-specific transcription activators. *Mol Cell* 1998;1:611–617.
27. Hahn SA, Schutte M, Hoque ATMS, et al. DPC4, a candidate tumor-suppressor gene at 18q21.1. *Science* 1996;271:350–353.
28. Goggins M, Shekher M, Turacioglu K, et al. Genetic alterations of the TGF beta receptor genes in pancreatic and biliary adenocarcinomas. *Cancer Res* 1998;58:5329–5332.
29. Baldwin RL, Friess H, Yokoyama M, et al. Attenuated ALK5 receptor expression in human pancreatic cancer: correlation with resistance to growth inhibition. *Int J Cancer* 1996;67:283–288.
30. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. *Nature* 1993;366:704–707.
31. Russo AA, Tong L, Lee JO, et al. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. *Nature* 1998;395:237–243.
32. Coleman KC, Wautlet BS, Morrissey D, et al. Identification of CDK4 sequences involved in cyclin D1 and p16 binding. *J Biol Chem* 1997;272:18869–18874.
33. Caldas C, Hahn SA, da Costa LT, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. *Nat Genet* 1994;8:27–31.
34. Schutte M, Hruban RH, Geradts J, et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. *Cancer Res* 1997;57:3126–3130.
35. Goldstein AM, Fraser MC, Struwing JP, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. *N Engl J Med* 1995;333:970–974.
36. Moskaluk CA, Hruban RH, Lietman AS, et al. Novel germline p16INK4A allele (Asp145Cys) in a family with multiple pancreatic carcinomas. *Hum Mutat* 1998;12:70.
37. Whelan AJ, Bartsch D, Goodfellow PJ. Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. *N Engl J Med* 1995;333:975–977.
38. Ciolti P, Strigini P, Bianchi-Scarra G. Familial melanoma and pancreatic cancer. *N Engl J Med* 1996;334:469–470.
39. Bartsch DK, Langer P, Habbe N, et al. Clinical and genetic analysis of 18 pancreatic carcinoma/melanoma-prone families. *Clin Genet* 2009;77:333–341.
40. Huang L, Lang D, Geradts J, et al. Molecular and immunohistochemical analyses of Rb1 and cyclin D1 in human ductal pancreatic carcinomas and cell lines. *Mol Carcinog* 1996;15:85–95.
41. Kern SE, Kinzler KW, Bruskin A, et al. Identification of p53 as a sequence-specific DNA-binding protein. *Science* 1991;252:1708–1711.
42. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. *Cell* 1993;75:817–825.
43. Kern SE, Pietenpol JA, Thiagalingam S, et al. Oncogenic forms of p53 inhibit p53-regulated gene expression. *Science* 1992;256:827–830.
44. Redston MS, Caldas C, Seymour AB, et al. WAF1, a potential mediator of p53 tumor suppression. *Cell* 1993;75:817–825.
45. Rozenblum E, Schutte M, Goggins M, et al. Tumor-suppressive pathways in pancreatic carcinoma. *Cancer Res* 1997;57:1731–1744.
46. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. *Nature* 1998;396:643–649.
47. Johansson B, Bardi G, Heim S, et al. Nonrandom chromosomal rearrangements in pancreatic carcinomas. *Cancer* 1992;69:1–8.
48. Griffin CA, Hruban RH, Morsberger LA, et al. Consistent chromosome abnormalities in adenocarcinoma of the pancreas. *Cancer Res* 1995;55:2394–2399.
49. Brat DJ, Hahn SA, Griffin CA, et al. The structural basis of molecular genetic deletions: An integration of classical cytogenetic and molecular analyses in pancreatic adenocarcinoma. *Am J Pathol* 1997;150:383–391.
50. Hahn SA, Seymour AB, Hoque ATMS, et al. Allelotype of pancreatic adenocarcinoma using a xenograft model. *Cancer Res* 1995;55:4670–4675.
51. Ionov Y, Peinado MA, Malkhosyan S, et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. *Nature* 1993;363:558–561.
52. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. *Science* 1993;260:816–819.
53. Aaltonen LA, Peltomäki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. *Science* 1993;260:812–816.
54. Yamamoto H, Itoh F, Nakamura H, et al. Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability. *Cancer Res* 2001;61:3139–3144.
55. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. *Science* 1995;268:1336–1338.
56. Hempen PM, Zhang L, Bansal RK, et al. Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers. *Cancer Res* 2003;63:994–999.
57. Rampino N, Yamamoto H, Ionov Y, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. *Science* 1997;275:967–969.
58. Day JD, DiGiuseppe JA, Yeo CJ, et al. Immunohistochemical evaluation of Her-2/neu oncogene expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. *Human Pathol* 1996;27:119–124.
59. Lei S, Appert HE, Nakata B, et al. Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival. *Int J Pancreatol* 1995;17:15–21.
60. Yamanaka Y, Friess H, Kobrin MS, et al. Overexpression of HER2/neu oncogene in human pancreatic carcinoma. *Hum Pathol* 1993;24:1127–1134.
61. Sakorafas GH, Lazaris A, Tsiotou AG, et al. Oncogenes in cancer of the pancreas. *Eur J Surg Oncol* 1995;21:251–253.
62. Preis M, Kore M. Signaling pathways in pancreatic cancer. *Crit Rev Eukaryot Gene Expr* 2011;21:115–129.
63. Matsubayashi H, Canto M, Sato N, et al. DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. *Cancer Res* 2006;66:1208–1217.

64. Jiang X, Hao HX, Growney JD, et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. *Proc Natl Acad Sci U S A* 2013;110:12649–12654.
65. Wu J, Jiao Y, Dal Molin M, et al. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. *Proc Natl Acad Sci U S A* 2011;108:21188–21193.
66. Wu J, Matthaei H, Maitra A, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. *Sci Transl Med* 2011;3:92ra66.
67. Kanda M, Knight S, Topazian M, et al. Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. *Gut* 2013;62:1024–1033.
68. Schonleben F, Qiu W, Ciau NT, et al. PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. *Clin Cancer Res* 2006;12:3851–3855.
69. Abraham SC, Klimstra DS, Wilentz RE, et al. Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. *Am J Pathol* 2002;160:1361–1369.
70. Abraham SC, Wu TT, Klimstra DS, et al. Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposis-associated pancreaticoblastomas: frequent alterations in the APC/beta-catenin pathway and chromosome 11p. *Am J Pathol* 2001;159:1619–16127.
71. Chung DC, Brown SB, Graeme-Cook F, et al. Localization of putative tumor suppressor loci by genome-wide allelotyping in human pancreatic endocrine tumors. *Cancer Res* 1998;58:3706–3711.
72. Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. *Science* 2011;331:1199–1203.
73. Heaphy CM, de Wilde RF, Jiao Y, et al. Altered telomeres in tumors with ATRX and DAXX mutations. *Science* 2011;333:425.
74. Yachida S, Vakiani E, White CM, et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. *Am J Surg Pathol* 2012;36:173–184.
75. Mizuta R, LaSalle JM, Cheng HL, et al. RAB22 and RAB163/mouse BRCA2: proteins that specifically interact with the RAD51 protein. *Proc Natl Acad Sci U S A* 1997;94:6927–6932.
76. Xia B, Sheng Q, Nakanishi K, et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. *Mol Cell* 2006;22:719–729.
77. Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. *Science* 2009;324:217.
78. Slater EP, Langer P, Niemczyk E, et al. PALB2 mutations in European familial pancreatic cancer families. *Clin Genet* 2010;78:490–494.
79. van der Heijden MS, Yeo CJ, Hruban RH, et al. Fanconi anemia gene mutations in young-onset pancreatic cancer. *Cancer Res* 2003;63:2585–2588.
80. Kern SE, Hruban RH, Hidalgo M, et al. An introduction to pancreatic carcinoma genetics, pathology, and therapy. *Cancer Biol Ther* 2002;1:607–613.
81. Moynahan ME, Cui TY, Jasin M. Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. *Cancer Res* 2001;61:4842–4850.
82. Tutt A, Bertwistle D, Valentine J, et al. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. *Embo J* 2001;20:4704–4716.
83. Gallmeier E, Calhoun ES, Rago C, et al. Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model of specific therapeutic options. *Gastroenterology* 2006;130:2145–2154.
84. Todd KE, Gloor B, Lane JS, et al. Resection of locally advanced pancreatic cancer after downstaging with continuous-infusion 5-fluorouracil, mitomycin-C, leucovorin, and dipyrindamole. *J Gastrointest Surg* 1998;2:159–166.
85. Takada T, Nimura Y, Katoh H, et al. Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial. *Hepatogastroenterology* 1998;45:2020–2026.
86. Sadoff L, Latino F. Complete clinical remission in a patient with advanced pancreatic cancer using mitomycin C-based chemotherapy: the role of adjunctive heparin. *Am J Clin Oncol* 1999;22:187–190.
87. Miura T, Endo Y, Matumoto Y, et al. [Intra-arterial infusion chemotherapy in combination with microwave hyperthermia for cancer of head of pancreas and liver metastasis—a case of 16 years survival]. *Gan To Kagaku Ryoho* 2000;27:1794–1800.
88. Vaughn C, Chapman J, Chinn B, et al. Activity of 5-fluorouracil, mitomycin C, and methyl CCNU in inoperable adenocarcinoma of pancreas. *Am J Clin Oncol* 1989;12:49–52.
89. James E, Waldron-Lynch MC, Saif MW. Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. *Anticancer Drugs* 2009;20:634–638.
90. Chalasani P, Kurtin S, Dragovich T. Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 mutation. *JOP* 2008;9:305–308.
91. Gallmeier E, Kern SE. Targeting Fanconi anemia/BRCA2 pathway defects in cancer: the significance of preclinical pharmacogenomic models. *Clin Cancer Res* 2007;13:4–10.
92. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. *N Engl J Med* 2009;361:123–134.
93. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. *Nature* 2013;500:415–421.
94. Ghosh S, Sur S, Yerram SR, et al. Hypersensitivities for acetaldehyde and other agents among cancer cells null for clinically-relevant Fanconi anemia genes. *Am J Pathol* 2014;184:260–270.
95. Axilbund JE, Argani P, Kamiyama M, et al. Absence of germline BRCA1 mutations in familial pancreatic cancer patients. *Cancer Biol Ther* 2009;8:131–135.
96. Al-Sukhni W, Rothenmund H, Borgida AE, et al. Germline BRCA1 mutations predispose to pancreatic adenocarcinoma. *Hum Genet* 2008;124:271–278.
97. Lal G, Liu G, Schmoeker B, et al. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. *Cancer Res* 2000;60:409–416.
98. Calhoun ES, Huel T, Gallmeier E, et al. Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays. *Cancer Res* 2006;66:7920–7928.
99. Scrimieri F, Calhoun ES, Patel K, et al. FAM190A rearrangements provide a multitude of individualized tumor signatures and neo-antigens in cancer. *Oncotarget* 2011;2:69–75.
100. Patel K, Scrimieri F, Ghosh S, et al. FAM190A deficiency creates a cell division defect. *Am J Pathol* 2013;183:296–303.
101. Polyak K, Li Y, Zhu H, et al. Somatic mutations of the mitochondrial genome in human colorectal tumours. *Nat Genet* 1998;20:291–293.
102. Fliiss MS, Usadel H, Caballero OL, et al. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. *Science* 2000;287:2017–2019.
103. Jones JB, Song JJ, Hempen PM, et al. Detection of mitochondrial DNA mutations in pancreatic cancer offers a “mass”-ive advantage over detection of nuclear DNA mutations. *Cancer Res* 2001;61:1299–1304.
104. Jones S, Li M, Parsons DW, et al. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. *Hum Mutat* 2011;33:100–103.
105. Shain AH, Giacomini CP, Matsukuma K, et al. Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. *Proc Natl Acad Sci U S A* 2012;109:E252–E259.
106. Su GH, Hilgers W, Shekher M, et al. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor-suppressor gene. *Cancer Res* 1998;58:2339–2342.
107. Teng DH-F, Perry III WL, Hogan JK, et al. Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. *Cancer Res* 1997;57:4177–4182.
108. Cunningham SC, Gallmeier E, Huel T, et al. Theoretical proposal: allele dosage of MAP2K4/MKK4 could rationalize frequent 17p loss in diverse human cancers. *Cell Cycle* 2006;5:1090–1093.
109. Hemminki A, Markie D, Tomlinson I, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. *Nature* 1998;391:184–187.
110. Jenne DE, Reimann H, Nezu J, et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. *Nature Genet* 1998;18:38–43.
111. Giardiello FM, Welsh SB, Hamilton SR, et al. Increased risk of cancer in the Peutz-Jeghers syndrome. *N Engl J Med* 1987;316:1511–1514.
112. Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. *Gastroenterology* 2000;119:1447–1453.
113. Su GH, Hruban RH, Bova GS, et al. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. *Am J Pathol* 1999;154:1835–1840.
114. Calhoun ES, Jones JB, Ashfaq R, et al. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. *Am J Pathol* 2003;163:1255–1260.
115. Iacobuzio-Donahue CA, van der Heijden MS, Baumgartner MR, et al. Large-scale allelotyping of pancreaticobiliary carcinoma provides quantitative estimates of genome-wide allelic loss. *Cancer Res* 2004;64:871–875.
116. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. *Nature* 1997;386:623–627.
117. Roberts NJ, Jiao Y, Yu J, et al. ATM mutations in patients with hereditary pancreatic cancer. *Cancer Discov* 2012;2:41–46.
118. Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. *Nature* 2012;491:399–405.
119. Whitcomb DC, Gorry MC, Preston RA, et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. *Nature Genet* 1996;14:141–145.
120. Lowenfels AB, Maisonneuve P, DiMaggio EP, et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. *J Natl Cancer Inst* 1997;89:442–446.